2023
Russomanno, G., Sison-Young, R., Livoti, L. A., Coghlan, H., Jenkins, R. E., Kunnen, S. J., . . . Copple, I. M. (2023). A systems approach reveals species differences in hepatic stress response capacity. TOXICOLOGICAL SCIENCES. doi:10.1093/toxsci/kfad085DOI: 10.1093/toxsci/kfad085
Gregory, G. L., & Copple, I. M. (2023). Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. MOLECULAR THERAPY-NUCLEIC ACIDS, 31, 211-223. doi:10.1016/j.omtn.2022.12.016DOI: 10.1016/j.omtn.2022.12.016
Dinkova-Kostova, A. T., & Copple, I. M. (2023). Advances and challenges in therapeutic targeting of NRF2. TRENDS IN PHARMACOLOGICAL SCIENCES, 44(3), 137-149. doi:10.1016/j.tips.2022.12.003DOI: 10.1016/j.tips.2022.12.003
2022
Ghallab, A., Hassan, R., Hofmann, U., Friebel, A., Hobloss, Z., Brackhagen, L., . . . Hengstler, J. G. (2022). Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. JOURNAL OF HEPATOLOGY, 77(1), 71-83. doi:10.1016/j.jhep.2022.01.020DOI: 10.1016/j.jhep.2022.01.020
2021
Chan, B. K. Y., Elmasry, M., Forootan, S. S., Russomanno, G., Bunday, T. M., Zhang, F., . . . Copple, I. M. (2021). Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration. HEPATOLOGY, 74(2), 973-986. doi:10.1002/hep.31859DOI: 10.1002/hep.31859
Copple, I. M., Park, B. K., & Goldring, C. E. (2021). Gene signatures reduce the stress of preclinical drug hepatotoxicity screening.. Hepatology (Baltimore, Md.). doi:10.1002/hep.31736DOI: 10.1002/hep.31736
2020
Weaver, R. J., Blomme, E. A., Chadwick, A. E., Copple, I. M., Gerets, H. H. J., Goldring, C. E., . . . Park, B. K. (2020). Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. NATURE REVIEWS DRUG DISCOVERY, 19(2), 131-148. doi:10.1038/s41573-019-0048-xDOI: 10.1038/s41573-019-0048-x
2019
Galea, I., Copple, I. M., Howat, D. W., & Franklin, S. (2019). SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 30, 257-261. doi:10.1016/j.msard.2019.02.027DOI: 10.1016/j.msard.2019.02.027
Tomlinison, L., Lu, Z. Q., Bentley, R., Colley, H., Murdoch, C., Webb, S., . . . Sharma, P. (n.d.). Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway. Biomedicine and Pharmacotherapy. doi:10.1016/j.biopha.2019.108637DOI: 10.1016/j.biopha.2019.108637
Copple, I. M., den Hollander, W., Callegaro, G., Mutter, F. E., Maggs, J. L., Schofield, A. L., . . . Park, B. K. (2019). Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Archives of Toxicology, 93, 385-399. doi:10.1007/s00204-018-2354-1DOI: 10.1007/s00204-018-2354-1
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2019). Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.. Oncotarget, 10(6), 685. doi:10.18632/oncotarget.26625DOI: 10.18632/oncotarget.26625
2018
Evans, J. P., Winiarski, B. K., Sutton, P. A., Jones, R. P., Ressel, L., Duckworth, C. A., . . . Kitteringham, N. R. (2018). The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 9(43), 27104-27116. doi:10.18632/oncotarget.25497DOI: 10.18632/oncotarget.25497
Lister, A., Bourgeois, S., Silva, P. H. I., Rubio-Aliaga, I., Marbet, P., Walsh, J., . . . Odermatt, A. (2018). NRF2 regulates the glutamine transporter Slc38a3 (SNAT3) in kidney in response to metabolic acidosis. SCIENTIFIC REPORTS, 8. doi:10.1038/s41598-018-24000-2DOI: 10.1038/s41598-018-24000-2
2017
Forootan, S. S., Mutter, F. E., Kipar, A., Iwawaki, T., Francis, B., Goldring, C. E., . . . Copple, I. M. (2017). Real-time in vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity. SCIENTIFIC REPORTS, 7, 11 pages. doi:10.1038/s41598-017-16491-2DOI: 10.1038/s41598-017-16491-2
Ogese, M. O., Faulkner, L., Jenkins, R. E., French, N. S., Copple, I. M., Antoine, D. J., . . . Naisbitt, D. J. (2017). Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells. TOXICOLOGICAL SCIENCES, 158(1), 76-89. doi:10.1093/toxsci/kfx069DOI: 10.1093/toxsci/kfx069
Clarke, J. I., Forootan, S. S., Lea, J. D., Howell, L. S., Rodriguez, J. M., Kipar, A., . . . Antoine, D. J. (2017). Circulating levels of miR-122 increase post-mortem, particularly following lethal dosing with pentobarbital sodium: implications for pre-clinical liver injury studies. TOXICOLOGY RESEARCH, 6(4), 406-411. doi:10.1039/c6tx00442cDOI: 10.1039/c6tx00442c
Optimising the use of medicines to reduce acute kidney injury in children and babies (Journal article)
Oni, L., Hawcutt, D. B., Turner, M. A., Beresford, M. W., McWilliam, S., Barton, C., . . . Antoine, D. J. (2017). Optimising the use of medicines to reduce acute kidney injury in children and babies. Pharmacology and Therapeutics, 174, 55-62. doi:10.1016/j.pharmthera.2017.02.018DOI: 10.1016/j.pharmthera.2017.02.018
A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance (Journal article)
O'Neill, P. M., Amewu, R. K., Charman, S. A., Sabbani, S., Gnädig, N. F., Straimer, J., . . . Ward, S. A. (2017). A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 8. doi:10.1038/ncomms15159DOI: 10.1038/ncomms15159
Copple, I. M., Dinkova-Kostova, A. T., Kensler, T. W., Liby, K. T., & Wigley, W. C. (2017). NRF2 as an Emerging Therapeutic Target. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017. doi:10.1155/2017/8165458DOI: 10.1155/2017/8165458
2016
Wong, M. H. L., Bryan, H. K., Copple, I. M., Jenkins, R. E., Chiu, P. H., Bibby, J., . . . Park, B. K. (2016). Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites. JOURNAL OF MEDICINAL CHEMISTRY, 59(6), 2396-2409. doi:10.1021/acs.jmedchem.5b01292DOI: 10.1021/acs.jmedchem.5b01292
Clarke, J. L., Murray, J. B., Park, B. K., & Copple, I. M. (2016). Roles of Nrf2 in drug and chemical toxicity. Current Opinion in Toxicology, 1, 104-110. doi:10.1016/j.cotox.2016.10.004DOI: 10.1016/j.cotox.2016.10.004
2015
Shelton, L. M., Lister, A., Walsh, J., Jenkins, R. E., Wong, M. H. L., Rowe, C., . . . Copple, I. M. (2015). Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. KIDNEY INTERNATIONAL, 88(06), 1261-1273. doi:10.1038/ki.2015.286DOI: 10.1038/ki.2015.286
Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress (Journal article)
Mutter, F. E., Park, B. K., & Copple, I. M. (2015). Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. BIOCHEMICAL SOCIETY TRANSACTIONS, 43, 657-662. doi:10.1042/BST20150044DOI: 10.1042/BST20150044
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2 (Journal article)
Olayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., . . . Park, B. K. (2015). Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. Free Radical Biology and Medicine, 78, 202-212. doi:10.1016/j.freeradbiomed.2014.11.003DOI: 10.1016/j.freeradbiomed.2014.11.003
2014
Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications (Journal article)
Walsh, J., Jenkins, R. E., Wong, M., Olayanju, A., Powell, H., Copple, I., . . . Park, B. K. (2014). Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: Biochemical, pharmacological and toxicological implications. JOURNAL OF PROTEOMICS, 108, 171-187. doi:10.1016/j.jprot.2014.05.007DOI: 10.1016/j.jprot.2014.05.007
Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids (Journal article)
Copple, I. M., Shelton, L. M., Walsh, J., Kratschmar, D. V., Lister, A., Odermatt, A., . . . Park, B. K. (2014). Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids. Toxicological Sciences, 140(2), 462-469. doi:10.1093/toxsci/kfu080DOI: 10.1093/toxsci/kfu080
Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids (Journal article)
Copple, I., Shelton, L. M., Walsh, J., Kratschmar, D. V., Lister, A., Odermatt, A., . . . Park, K. (2014). Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids. Toxicological Sciences, 140(2), 462-469. doi:10.1093/toxsci/kfu080DOI: 10.1093/toxsci/kfu080
2013
The S349T mutation of <i>SQSTM1</i> links Keap1/Nrf2 signalling to Paget's disease of bone (Journal article)
Wright, T., Rea, S. L., Goode, A., Bennett, A. J., Ratajczak, T., Long, J. E., . . . Layfield, R. (2013). The S349T mutation of <i>SQSTM1</i> links Keap1/Nrf2 signalling to Paget's disease of bone. BONE, 52(2), 699-706. doi:10.1016/j.bone.2012.10.023DOI: 10.1016/j.bone.2012.10.023
Role of Nrf2 in protection against acute kidney injury (Journal article)
Shelton, L. M., Park, B. K., & Copple, I. M. (2013). Role of Nrf2 in protection against acute kidney injury. KIDNEY INTERNATIONAL, 84(6), 1090-1095. doi:10.1038/ki.2013.248DOI: 10.1038/ki.2013.248
2012
Copple, I. M., Mercer, A. E., Firman, J., Donegan, G., Herpers, B., Wong, M. H. L., . . . Park, B. K. (2012). Examination of the Cytotoxic and Embryotoxic Potential and Underlying Mechanisms of Next-Generation Synthetic Trioxolane and Tetraoxane Antimalarials. MOLECULAR MEDICINE, 18(7), 1045-1055. doi:10.2119/molmed.2012.00154DOI: 10.2119/molmed.2012.00154
The Keap1-Nrf2 Cell Defense Pathway - A Promising Therapeutic Target? (Journal article)
Copple, I. M. (2012). The Keap1-Nrf2 Cell Defense Pathway - A Promising Therapeutic Target?. CURRENT CONCEPTS IN DRUG METABOLISM AND TOXICOLOGY, 63, 43-79. doi:10.1016/B978-0-12-398339-8.00002-1DOI: 10.1016/B978-0-12-398339-8.00002-1
2011
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy (Journal article)
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., . . . Park, B. K. (2011). Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. MOLECULAR CANCER, 10. doi:10.1186/1476-4598-10-37DOI: 10.1186/1476-4598-10-37
The Role of Heme and the Mitochondrion in the Chemical and Molecular Mechanisms of Mammalian Cell Death Induced by the Artemisinin Antimalarials (Journal article)
Mercer, A. E., Copple, I. M., Maggs, J. L., O'Neill, P. M., & Park, B. K. (2011). The Role of Heme and the Mitochondrion in the Chemical and Molecular Mechanisms of Mammalian Cell Death Induced by the Artemisinin Antimalarials. JOURNAL OF BIOLOGICAL CHEMISTRY, 286(2), 987-996. doi:10.1074/jbc.M110.144188DOI: 10.1074/jbc.M110.144188
2010
Physical and Functional Interaction of Sequestosome 1 with Keap1 Regulates the Keap1-Nrf2 Cell Defense Pathway (Journal article)
Copple, I. M., Lister, A., Obeng, A. D., Kitteringham, N. R., Jenkins, R. E., Layfield, R., . . . Park, B. K. (2010). Physical and Functional Interaction of Sequestosome 1 with Keap1 Regulates the Keap1-Nrf2 Cell Defense Pathway. JOURNAL OF BIOLOGICAL CHEMISTRY, 285(22), 16782-16788. doi:10.1074/jbc.M109.096545DOI: 10.1074/jbc.M109.096545
The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity. (Journal article)
Copple, I. M., Goldring, C. E., Kitteringham, N. R., & Park, B. K. (2010). The keap1-nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity.. Handbook of experimental pharmacology, (196), 233-266. doi:10.1007/978-3-642-00663-0_9DOI: 10.1007/978-3-642-00663-0_9
2009
Extract of <i>Ginkgo biloba</i> induces glutathione-S-transferase subunit-P1 <i>in vitro</i> (Journal article)
Liu, X. -P., Goldring, C. E. P., Wang, H. -Y., Copple, I. M., Kitteringham, N. R., & Park, B. K. (2009). Extract of <i>Ginkgo biloba</i> induces glutathione-S-transferase subunit-P1 <i>in vitro</i>. PHYTOMEDICINE, 16(5), 451-455. doi:10.1016/j.phymed.2008.11.001DOI: 10.1016/j.phymed.2008.11.001
2008
The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system (Journal article)
Copple, I. M., Goldring, C. E., Jenkins, R. E., Chia, A. J. L., Randle, L. E., Hayes, J. D., . . . Park, B. K. (2008). The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. HEPATOLOGY, 48(4), 1292-1301. doi:10.1002/hep.22472DOI: 10.1002/hep.22472
The Nrf2-Keapl defence pathway: Role in protection against drug-induced toxicity (Journal article)
Copple, I. M., Goldring, C. E., Kitteringham, N. R., & Park, B. K. (2008). The Nrf2-Keapl defence pathway: Role in protection against drug-induced toxicity. TOXICOLOGY, 246(1), 24-33. doi:10.1016/j.tox.2007.10.029DOI: 10.1016/j.tox.2007.10.029
Extract of <i>Ginkgo biloba</i> induces glutamate cysteine ligase catalytic subunit (GCLC) (Journal article)
Liu, X. -P., Goldring, C. E. P., Wang, H. -Y., Copple, I. M., Kitteringharn, N. R., Park, B. K., & Wei, W. (2008). Extract of <i>Ginkgo biloba</i> induces glutamate cysteine ligase catalytic subunit (GCLC). PHYTOTHERAPY RESEARCH, 22(3), 367-371. doi:10.1002/ptr.2328DOI: 10.1002/ptr.2328
2007
Extract of <i>Ginkgo biloba</i> induces phase 2 genes through Keap1-Nrf2-ARE signaling pathway (Journal article)
Liu, X. -P., Goldring, C. E. P., Copple, I. M., Wang, H. -Y., Wei, W., Kitteringham, N. R., & Park, B. K. (2007). Extract of <i>Ginkgo biloba</i> induces phase 2 genes through Keap1-Nrf2-ARE signaling pathway. LIFE SCIENCES, 80(17), 1586-1591. doi:10.1016/j.lfs.2007.01.034DOI: 10.1016/j.lfs.2007.01.034
2006
Plasticity in cell defence: access to and reactivity of critical protein residues and DNA response elements (Journal article)
Goldring, C., Kitteringham, N., Jenkins, R., Copple, I., Jeannin, J. F., & Park, B. K. (2006). Plasticity in cell defence: access to and reactivity of critical protein residues and DNA response elements. JOURNAL OF EXPERIMENTAL BIOLOGY, 209(12), 2337-2343. doi:10.1242/jeb.02209DOI: 10.1242/jeb.02209